2Seventy Bio Inc banner

2Seventy Bio Inc
NASDAQ:TSVT

Watchlist Manager
2Seventy Bio Inc Logo
2Seventy Bio Inc
NASDAQ:TSVT
Watchlist
Price: 5 USD
Market Cap: $266.2m

Relative Value

The Relative Value of one TSVT stock under the Base Case scenario is 2.59 USD. Compared to the current market price of 5 USD, 2Seventy Bio Inc is Overvalued by 48%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TSVT Relative Value
Base Case
2.59 USD
Overvaluation 48%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

TSVT Competitors Multiples
2Seventy Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
2Seventy Bio Inc
NASDAQ:TSVT
257.9m USD 6.8 -4.5 -0.9 -0.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
387.4B USD 6.5 166 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
201.5B USD 5.5 26 14.9 14.9
US
Gilead Sciences Inc
NASDAQ:GILD
186.3B USD 6.4 23 15.6 15.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.8B USD 10.1 32.1 23.6 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.5B USD 5.7 18 15.3 17.5
AU
CSL Ltd
ASX:CSL
87.1B AUD 3.9 20.2 13.5 16.8
NL
argenx SE
XBRU:ARGX
41.9B EUR 14.2 33.3 56.8 58.4
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
US
2Seventy Bio Inc
NASDAQ:TSVT
Average P/S: 3 058 675.6
6.8
29%
0.2
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.5
2%
2.7
US
Gilead Sciences Inc
NASDAQ:GILD
6.4
4%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
8%
0.7
AU
CSL Ltd
ASX:CSL
3.9
5%
0.8
NL
argenx SE
XBRU:ARGX
14.2
49%
0.3
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
US
2Seventy Bio Inc
NASDAQ:TSVT
Average P/E: 45.5
Negative Multiple: -4.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26
18%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
23
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
20.2
11%
1.8
NL
argenx SE
XBRU:ARGX
33.3
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
2Seventy Bio Inc
NASDAQ:TSVT
Average EV/EBITDA: 22.3
Negative Multiple: -0.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.9
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
15.6
7%
2.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
24%
0.6
AU
CSL Ltd
ASX:CSL
13.5
8%
1.7
NL
argenx SE
XBRU:ARGX
56.8
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
2Seventy Bio Inc
NASDAQ:TSVT
Average EV/EBIT: 24.4
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
14.9
2%
7.5
US
Gilead Sciences Inc
NASDAQ:GILD
15.6
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
23%
0.8
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
NL
argenx SE
XBRU:ARGX
58.4
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A